Novartis NVS obtains FDA ... disease. Approximately 50% of patients with persistent proteinuria progress to kidney failure within 10 to 20 years of diagnosis. The approval Vanrafia marks the third ...

The Food and Drug Administration approved Novo Nordisk's Ozempic for patients with both chronic kidney disease and diabetes, ...

Novartis has made kidney disorders ... trying to slow disease progression. The lone therapeutic is tolvaptan, brand name Jynarque, an Otsuka Pharmaceutical drug approved by the FDA in 2018 for ...

The FDA has ... sickle cell drug from Epidestiny. Novartis has grown in renal diseases once again with a $1.7bn deal to buy Regulus and its autosomal dominant polycystic kidney disease (ADPKD ...

giving the Swiss drugmaker access to an experimental drug to treat a life-threatening kidney disease. Under the deal terms, Novartis will pay $7 per share in cash upfront, or about $800 million ...